Rafa: Midazolam Autoinjector

2022: Device Announcement

On August 30, 2022, Rafa Laboratories announced the release, according to the company, of the first midazolam auto-injector on the market to treat epileptic status or long-term seizures. The Israeli company created this device in conjunction with the Joint Executive Office of the US Department of Defense Chemical, Biological, Radiological and Nuclear Protection Programs (JPEO-CBRND).

The 10 mg midazolam autoinjector from Rafa Laboratories can be used to treat epileptic status in adults. This means that the autoinjector can be used to treat seizures resulting from exposure to the nerve agent. JPEO-CBRND has determined that the autoinjector improves and replaces the August 2022 anticonvulsant nerve agent antidote (CANA), the diazepam autoinjector.

The first on-market automatic device for injecting midazolam in the event of long-term seizures has been released

The autoinjector is injected intramuscularly into the thigh in a simple and rapid way that does not require an intravenous line, it can be injected through clothing. These are significant benefits in the field during an emergency, where rapid treatment reduces the likelihood of irreversible damage that can result from a continuous attack, Rafa Laboratories said in a news release.

{{quote 'The ease of use of the auto-injector has a significant medical advantage in its immediate therapeutic effect, as well as in reducing long-term damage! Clinical studies have confirmed a correlation between early treatment of epileptic status and reduced risk of ongoing and irreversible neurological damage. This product can help save many lives around the world, "said Roy Shay, head of emergency solutions at Rafa Laboratories. }} Rafa Laboratories said the approval FDA followed an expedited review. The product was developed Israel in and manufactured at the company's facility in Jerusalem. It is already being sold under an emergency use permit in other territories.^[1]

Notes